MATRIX ACCUMULATION IN MESANGIAL CELLS EXPOSED TO CYCLOSPORINE A REQUIRES A PERMISSIVE GENETIC BACKGROUND

Background. Chronic nephrotoxicity is an important adverse effect of cyclosporine A (CsA) therapy. Tubulo-interstitial lesions and arteriolopathy are common histologic findings. Glomerular lesions are also described, but they are of variable severity. The aim of our study is to determine whether CsA has a direct effect on mesangial cells and whether the cellular response depends on the genetic background. Methods. We studied mesangial cells isolated from mice susceptible (ROP/Le-+Es1b/+Es1a, ROP) and resistant to glomerulosclerosis (B6SJLF1, C57). We previously showed that sclerosis-prone and sclerosis-resistant phenotypes are maintained in vitro. We examined whether CsA exposure directly affected extracellular matrix turnover in mesangial cells and whether the response is determined by the genetic background. Extracellular matrix synthesis and degradation were studied by proline incorporation, ELISA, reverse transcription-polymerase chain reaction, zymography, and reverse zymography. We chose a CsA dose that induced neither cytotoxicity nor apoptosis (1 &mgr;g/ml). Results. At the dose of 1 &mgr;g/ml total collagen accumulation was increased in ROP but not in C57 cells. Matrix metalloproteinase (MMP)-2 activity and mRNA levels were selectively decreased in ROP cells. CsA exposure did not affect tissue inhibitors of MMP (TIMP)-1 and -2 activity or TGF-&bgr;1 mRNA expression and protein synthesis in either cell line. Conclusion. CsA increases total collagen accumulation in mesangial cells from sclerosis-prone mice by decreasing MMP-2 activity, but does not affect cells from sclerosis-resistant mice. Thus, CsA directly affects mesangial cells, but only those with a permissive genetic background for glomerulosclerosis.

[1]  G. Striker,et al.  IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. , 1999, Diabetes.

[2]  C. Pollock,et al.  Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[3]  G. Striker,et al.  Nature and severity of the glomerular response to nephron reduction is strain-dependent in mice. , 1999, The American journal of pathology.

[4]  G. Striker,et al.  Glomerular endothelial cells synthesize collagens but little gelatinase A and B. , 1998, Journal of the American Society of Nephrology : JASN.

[5]  S. Dauwe,et al.  Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. , 1998, Kidney international.

[6]  L. Gesualdo,et al.  Additive effect of cyclosporine and low density lipoproteins on transforming growth factor-beta 1 and monocyte chemotactic protein-1 expression in human mesangial cells. , 1998, Transplantation proceedings.

[7]  V. Cairns,et al.  TGF-β: A Link Between Immunosuppression, Nephrotoxicity, and CsA , 1998 .

[8]  M. Nicholson,et al.  Is TGF-β a Profibrotic Cytokine in Human Renal Transplants? , 1998 .

[9]  A. Baker,et al.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. , 1998, The Journal of clinical investigation.

[10]  K. Oka,et al.  Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. , 1998, Transplantation proceedings.

[11]  G. Striker,et al.  Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[12]  F. Shihab Cyclosporine nephropathy: pathophysiology and clinical impact. , 1996, Seminars in nephrology.

[13]  F. Cosio,et al.  Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. , 1996, Transplantation.

[14]  N. Perico,et al.  Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. , 1996, Transplantation.

[15]  N. Perico,et al.  Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. , 1996, Kidney international.

[16]  W. Bennett,et al.  Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. , 1996, Kidney international.

[17]  G. Striker,et al.  Dissociation of glomerular hypertrophy, cell proliferation, and glomerulosclerosis in mouse strains heterozygous for a mutation (Os) which induces a 50% reduction in nephron number. , 1996, The Journal of clinical investigation.

[18]  G. Striker,et al.  Relationships between mesangial cell proliferation and types I and IV collagen mRNA levels in vitro. , 1995, The American journal of physiology.

[19]  G. Striker,et al.  Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. , 1995, Journal of the American Society of Nephrology : JASN.

[20]  Y. Tomino,et al.  Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. , 1994, Renal physiology and biochemistry.

[21]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Ghiggeri,et al.  Cyclosporine enhances the synthesis of selected extracellular matrix proteins by renal cells "in culture". Different cell responses and phenotype characterization. , 1994, Transplantation.

[23]  G. Striker,et al.  Age-related changes in alpha 1- and alpha 2-chain type IV collagen mRNAs in adult mouse glomeruli: competitive PCR. , 1992, The American journal of physiology.

[24]  N. Perico,et al.  Cyclosporine-induced renal dysfunction in experimental animals and humans. , 1991, Kidney international. Supplement.

[25]  G. Wolf,et al.  Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. , 1990, Journal of the American Society of Nephrology : JASN.

[26]  G. Striker,et al.  Synthesis and release of insulinlike growth factor I by mesangial cells in culture. , 1988, The American journal of physiology.

[27]  G. Striker,et al.  Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells. , 1988, Endocrinology.

[28]  G. Striker,et al.  Human glomerular visceral epithelial cells synthesize a basal lamina collagen in vitro. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Diegelmann,et al.  Collagen biosynthesis during connective tissue development in chick embryo. , 1972, Developmental biology.

[30]  M. Nicholson,et al.  Is TGF-beta a profibrotic cytokine in human renal transplants? , 1998, Transplantation proceedings.

[31]  V. Cairns,et al.  TGF-beta: a link between immunosuppression, nephrotoxicity, and CsA. , 1998, Transplantation proceedings.

[32]  G. Striker,et al.  Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. , 1998, Kidney international.

[33]  L. Racusen,et al.  Glomerular metalloprotease activity in streptozotocin- treated rats and in spontaneously diabetic rats (BB/DP). , 1994, Life sciences.

[34]  G. Striker,et al.  Studies by competitive PCR of glomerulosclerosis in growth hormone transgenic mice. , 1993, Kidney international. Supplement.

[35]  G. Wolf,et al.  Increases in levels of collagen types I and IV messenger ribonucleic acid in murine kidneys after treatment with ciclosporin. , 1992, Nephron.

[36]  W. Bennett,et al.  Cyclosporine nephrotoxicity. , 2003, Seminars in nephrology.